Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy
Comprehensive safety tracking of CAR-T therapy in myeloma reveals rare but serious side effects like movement disorders and gut inflammation clinicians must watch for.
This review synthesizes the safety profile of BCMA-targeted CAR-T therapies in relapsed/refractory myeloma, cataloguing both well-characterized toxicities (CRS, ICANS, infections) and rarer events including parkinsonian-like movement disorders, immune enterocolitis, and secondary malignancies. Comprehensive toxicity awareness is essential for preventing non-relapse mortality.
What the study was
- Study design
- Narrative review of BCMA CAR-T safety data
- Population
- Relapsed/refractory multiple myeloma patients receiving approved BCMA-targeted CAR-T therapies
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- BioDrugs
Why it surfaced
Solid safety review for established BCMA CAR-T therapies. Clinical utility for practitioners managing myeloma patients. Lower novelty (review of existing data), but rare toxicities section adds value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.